381 related articles for article (PubMed ID: 25704363)
1. Outcome and prognostic factors for children with supratentorial primitive neuroectodermal tumors treated with carboplatin during radiotherapy: a report from the Children's Oncology Group.
Jakacki RI; Burger PC; Kocak M; Boyett JM; Goldwein J; Mehta M; Packer RJ; Tarbell NJ; Pollack IF
Pediatr Blood Cancer; 2015 May; 62(5):776-83. PubMed ID: 25704363
[TBL] [Abstract][Full Text] [Related]
2. Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): report of the Head Start I and II experience.
Fangusaro J; Finlay J; Sposto R; Ji L; Saly M; Zacharoulis S; Asgharzadeh S; Abromowitch M; Olshefski R; Halpern S; Dubowy R; Comito M; Diez B; Kellie S; Hukin J; Rosenblum M; Dunkel I; Miller DC; Allen J; Gardner S
Pediatr Blood Cancer; 2008 Feb; 50(2):312-8. PubMed ID: 17668858
[TBL] [Abstract][Full Text] [Related]
3. Non-pineal supratentorial primitive neuro-ectodermal tumors (sPNET) in teenagers and young adults: Time to reconsider cisplatin based chemotherapy after cranio-spinal irradiation?
Biswas S; Burke A; Cherian S; Williams D; Nicholson J; Horan G; Jefferies S; Williams M; Earl HM; Burnet NG; Hatcher H
Pediatr Blood Cancer; 2009 Jul; 52(7):796-803. PubMed ID: 19202566
[TBL] [Abstract][Full Text] [Related]
4. Treatment of young children with CNS-primitive neuroectodermal tumors/pineoblastomas in the prospective multicenter trial HIT 2000 using different chemotherapy regimens and radiotherapy.
Friedrich C; von Bueren AO; von Hoff K; Gerber NU; Ottensmeier H; Deinlein F; Benesch M; Kwiecien R; Pietsch T; Warmuth-Metz M; Faldum A; Kuehl J; Kortmann RD; Rutkowski S
Neuro Oncol; 2013 Feb; 15(2):224-34. PubMed ID: 23223339
[TBL] [Abstract][Full Text] [Related]
5. A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET.
Chintagumpala M; Hassall T; Palmer S; Ashley D; Wallace D; Kasow K; Merchant TE; Krasin MJ; Dauser R; Boop F; Krance R; Woo S; Cheuk R; Lau C; Gilbertson R; Gajjar A
Neuro Oncol; 2009 Feb; 11(1):33-40. PubMed ID: 18796696
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors and treatment results for supratentorial primitive neuroectodermal tumors in children using radiation and chemotherapy: a Childrens Cancer Group randomized trial.
Cohen BH; Zeltzer PM; Boyett JM; Geyer JR; Allen JC; Finlay JL; McGuire-Cullen P; Milstein JM; Rorke LB; Stanley P
J Clin Oncol; 1995 Jul; 13(7):1687-96. PubMed ID: 7602359
[TBL] [Abstract][Full Text] [Related]
7. Patterns of treatment failure in infants with primitive neuroectodermal tumors who were treated on CCG-921: a phase III combined modality study.
Hong TS; Mehta MP; Boyett JM; Donahue B; Rorke LB; Zeltzer PM
Pediatr Blood Cancer; 2005 Oct; 45(5):676-82. PubMed ID: 16007595
[TBL] [Abstract][Full Text] [Related]
8. High-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk or relapsed medulloblastoma or supratentorial primitive neuroectodermal tumor.
Sung KW; Yoo KH; Cho EJ; Koo HH; Lim DH; Shin HJ; Ahn SD; Ra YS; Choi ES; Ghim TT
Pediatr Blood Cancer; 2007 Apr; 48(4):408-15. PubMed ID: 17066462
[TBL] [Abstract][Full Text] [Related]
9. Supratentorial primitive neuroectodermal tumors (S-PNET) in children: A prospective experience with adjuvant intensive chemotherapy and hyperfractionated accelerated radiotherapy.
Massimino M; Gandola L; Spreafico F; Luksch R; Collini P; Giangaspero F; Simonetti F; Casanova M; Cefalo G; Pignoli E; Ferrari A; Terenziani M; Podda M; Meazza C; Polastri D; Poggi G; Ravagnani F; Fossati-Bellani F
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1031-7. PubMed ID: 16343801
[TBL] [Abstract][Full Text] [Related]
10. Relapse patterns in pediatric embryonal central nervous system tumors.
Perreault S; Lober RM; Carret AS; Zhang G; Hershon L; Décarie JC; Yeom K; Vogel H; Fisher PG; Partap S
J Neurooncol; 2013 Nov; 115(2):209-15. PubMed ID: 23921420
[TBL] [Abstract][Full Text] [Related]
11. Treatment Outcome and Prognostic Molecular Markers of Supratentorial Primitive Neuroectodermal Tumors.
Choi SH; Kim SH; Shim KW; Han JW; Choi J; Kim DS; Lyu CJ; Kim JW; Suh CO; Cho J
PLoS One; 2016; 11(4):e0153443. PubMed ID: 27074032
[TBL] [Abstract][Full Text] [Related]
12. Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: a Children's Oncology Group Phase I/II study.
Jakacki RI; Burger PC; Zhou T; Holmes EJ; Kocak M; Onar A; Goldwein J; Mehta M; Packer RJ; Tarbell N; Fitz C; Vezina G; Hilden J; Pollack IF
J Clin Oncol; 2012 Jul; 30(21):2648-53. PubMed ID: 22665539
[TBL] [Abstract][Full Text] [Related]
13. Outcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation, and chemotherapy.
Reddy AT; Janss AJ; Phillips PC; Weiss HL; Packer RJ
Cancer; 2000 May; 88(9):2189-93. PubMed ID: 10813733
[TBL] [Abstract][Full Text] [Related]
14. Outcome for children <4 years of age with malignant central nervous system tumors treated with high-dose chemotherapy and autologous stem cell rescue.
Thorarinsdottir HK; Rood B; Kamani N; Lafond D; Perez-Albuerne E; Loechelt B; Packer RJ; MacDonald TJ
Pediatr Blood Cancer; 2007 Mar; 48(3):278-84. PubMed ID: 16456857
[TBL] [Abstract][Full Text] [Related]
15. Evolving of therapeutic strategies for CNS-PNET.
Massimino M; Gandola L; Biassoni V; Spreafico F; Schiavello E; Poggi G; Pecori E; Vajna De Pava M; Modena P; Antonelli M; Giangaspero F
Pediatr Blood Cancer; 2013 Dec; 60(12):2031-5. PubMed ID: 23852767
[TBL] [Abstract][Full Text] [Related]
16. Low-dose craniospinal irradiation and ifosfamide, cisplatin and etoposide for non-metastatic embryonal tumors in the central nervous system.
Yasuda K; Taguchi H; Sawamura Y; Ikeda J; Aoyama H; Fujieda K; Ishii N; Kashiwamura M; Iwasaki Y; Shirato H
Jpn J Clin Oncol; 2008 Jul; 38(7):486-92. PubMed ID: 18573848
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of preradiotherapy chemotherapy followed by hyperfractionated radiotherapy for newly diagnosed high-risk medulloblastoma/primitive neuroectodermal tumor: a report from the Children's Oncology Group (CCG 9931).
Allen J; Donahue B; Mehta M; Miller DC; Rorke LB; Jakacki R; Robertson P; Sposto R; Holmes E; Vezina G; Muraszko K; Puccetti D; Prados M; Chan KW
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1006-11. PubMed ID: 19356859
[TBL] [Abstract][Full Text] [Related]
18. Differential responsiveness among "high risk" pediatric brain tumors in a pilot study of dose-intensive induction chemotherapy.
Jennings MT; Cmelak A; Johnson MD; Moots PL; Pais R; Shyr Y
Pediatr Blood Cancer; 2004 Jul; 43(1):46-54. PubMed ID: 15170889
[TBL] [Abstract][Full Text] [Related]
19. Survival of infants with primitive neuroectodermal tumors or malignant ependymomas of the CNS treated with eight drugs in 1 day: a report from the Childrens Cancer Group.
Geyer JR; Zeltzer PM; Boyett JM; Rorke LB; Stanley P; Albright AL; Wisoff JH; Milstein JM; Allen JC; Finlay JL
J Clin Oncol; 1994 Aug; 12(8):1607-15. PubMed ID: 8040673
[TBL] [Abstract][Full Text] [Related]
20. Outcome for children treated for medulloblastoma and supratentorial primitive neuroectodermal tumor (CNS-PNET) - a retrospective analysis spanning 40 years of treatment.
Stensvold E; Krossnes BK; Lundar T; Due-Tønnessen BJ; Frič R; Due-Tønnessen P; Bechensteen AG; Myklebust TÅ; Johannesen TB; Brandal P
Acta Oncol; 2017 May; 56(5):698-705. PubMed ID: 28325133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
